Vir Biotechnology (VIR) stock jumps as the company inks a licensing deal worth up to $1.9B with Gilead (GILD) to develop ...

India’s cancer burden hit 15.70 lakh cases in 2025. But with returns diverging and valuations stretching, which ...

The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.

DataM Intelligence’s report analyzes therapy, stage, end-user and regional segments, including pipeline developments, company ...

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction.

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory ...

Vopimetostat combinations with RAS (ON) inhibitors daraxonrasib or zoldonrasib continued to be generally well-tolerated Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line ...

Moderna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release.

Months before Vancouver-based Zymeworks agreed to license its experimental cancer treatment to Roche, the biotechnology company had already identified two Roche-linked drugs among its potential ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study ...

From AI risk assessment to tests that help you choose the best course of treatment, breast cancer innovations are moving us ...

REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for ...